
Adding durvalumab to BCG induction and maintenance reduced high-risk recurrences in patients with papillary-only bladder tumors in POTOMAC.

Adding durvalumab to BCG induction and maintenance reduced high-risk recurrences in patients with papillary-only bladder tumors in POTOMAC.

Perioperative enfortumab vedotin plus pembrolizumab showed no clinically meaningful HRQOL detriment in cisplatin-eligible MIBC.

Johanna Enke, MD, discusses safety findings from a phase 2 study of lutetium Lu 177 vipivotide tetraxetan rechallenge in mCRPC.

The claudin 6–targeted antibody-drug conjugate ixotatug vedotin showed antitumor activity in recurrent germ cell tumors, including after transplant.

An exploratory analysis of the phase 3 KEYNOTE-B15 trial found that ctDNA status was strongly prognostic for event-free survival regardless of treatment arm.

The KEYNOTE-866 trial did not meet its EFS primary end point with perioperative pembrolizumab added to neoadjuvant cisplatin and gemcitabine.

The sacituzumab govitecan, enfortumab vedotin, and zimberelimab triplet produced early, durable responses in untreated metastatic urothelial cancer.

Efficacy outcomes in KEYNOTE-905 were consistent with a contribution of both enfortumab vedotin and pembrolizumab in cisplatin-ineligible MIBC.

Perioperative nivolumab plus neoadjuvant chemotherapy did not significantly improve pCR rate or event-free survival in MIBC.

Saruparib plus an androgen receptor pathway inhibitor was safe and active in metastatic prostate cancer.

Atezolizumab plus BCG did not extend EFS vs BCG alone in BCG-naive, high-risk non–muscle invasive bladder cancer.

A reduced docetaxel regimen helped lower rates of AEs when combined with daolutamide and ADT in mHSPC.

Adjuvant atezolizumab improved DFS and OS in patients with muscle-invasive bladder cancer who tested positive for ctDNA after radical cystectomy.

Lutetium Lu 177 vipivotide tetraxetan plus an ARPI and ADT improved rPFS in metastatic hormone-sensitive prostate cancer.

Frontline disitamab vedotin plus toripalimab significantly improved PFS and OS in HER2-expressing locally advanced or metastatic urothelial carcinoma.

Enzalutamide plus leuprolide acetate led to a 40.3% lower risk of death vs leuprolide acetate alone in high-risk, biochemically recurrent prostate cancer.

Capivasertib plus abiraterone acetate, prednisone, and androgen deprivation therapy was active in PTEN-deficient de novo metastatic HSPC.

Enfortumab vedotin plus pembrolizumab significantly improved survival and pCR vs surgery alone in cisplatin-ineligible MIBC per KEYNOTE-905 data.

Kim Nguyen Chi, MD, FRCPC, discusses correlative analyses of prognostic subgroups in the phase 2 PR21 study in PSMA-positive mCRPC.

Srikala Sridhar, MD, MSc, FRCPC, discusses efficacy findings from the ALPACA study and the necessity of improved patient selection for checkpoint inhibitors in PSCC

Datopotamab deruxtecan plus rilvegostomig was active in cisplatin-ineligible and platinum-pretreated locally advanced or metastatic urothelial cancer.

Lenvatinib plus everolimus improved PFS vs cabozantinib in metastatic clear cell renal cell carcinoma after progression on a PD-1 inhibitor.

Belzutifan plus pembrolizumab and lenvatinib improved efficacy outcomes compared with multiple other pembrolizumab-based triplet regimens in advanced clear cell renal cell carcinoma.

RNAseq-defined clusters guided treatment selection in metastatic ccRCC in the phase 2 OPTIC trial, yielding a 76% ORR with cabozantinib plus nivolumab.

Fruquintinib plus sintilimab significantly extended progression-free survival in advanced RCC following first-line VEGFR TKI therapy.

SunRISe-4 data show that TAR-200 and cetrelimab led to a high pCR and 12-month RFS rate in muscle-invasive bladder cancer.

Durvalumab plus BCG induction and maintenance therapy yielded clinically meaningful improvement in DFS vs BCG induction and maintenance therapy alone in BCG-naive, high-risk NMIBC.

Andrea Necchi, MD, discusses the role of minimal residual disease assessment in the phase 2 SunRISe-4 trial evaluating TAR-200 plus cetrelimab in MIBC.

Five year follow up results from CheckMate 274 support adjuvant nivolumab as a standard of care for high-risk muscle-invasive urothelial carcinoma.

Experts in genitourinary oncology share key insights on the most anticipated data and abstracts expected to shape discussions at the 2025 ESMO Congress.